Top Story
J&J, Stryker execs predict elective surgeries to rebound
Johnson & Johnson ($JNJ) and Stryker ($SYK) executives are predicting a rebound in elective surgeries as patients decide to undergo procedures they've been putting off due to the economy. However, it is difficult to determine when this will occur. The predictions came during the companies' respective earnings calls Tuesday. News
Latest News
Also Noted
> Abbott Laboratories ($ABT) fell the most in two months after fourth-quarter sales came in below analyst estimates. Sales of its heart stents fell due to competition. Story
> Quest Diagnostics cheered analysts with higher-than-expected quarterly earnings, sending its shares up more than 6%. Report
> While a banner is touting India's launch of a $35 tablet computer, Medtronic ($MDT) is eyeing the potential to launch a similar low-cost revolution in medical devices like pacemakers. News
> Device manufacturers want the U.S. government and health insurers to cover weight-loss surgery in an effort to help more obese Americans. Report
Read more >>Press Releases
Popular Comment Threads
Special Report
Top 10 medical device deals of 2011
There was a frenzy of medical device deals in 2011, with some big names entering the fray, including pharmaceutical and device titan Johnson & Johnson ($JNJ). In fact, J&J took the top spot on the list with its $21.3 billion buyout of Synthes. The buy, which is undergoing review by EU authorities, is the largest in the healthcare giant's history and will make it a leader in the orthopedics market. See the top 10 deals >>
Special Report
5 Innovative Michigan companies
Michigan is traditionally known for its preeminence in the auto industry and beautiful scenery. It's also gaining recognition for its booming life sciences industry--particularly medical devices. This report profiles 5 companies with promising technologies, ranging from breast cancer detectors to a smartphone that keeps constant track of potential arrhymthmia patient's hear data. This is not a ranking, but rather a sample of what the Wolverine State has to offer. Click here to start report
Biotech News
- UPDATED: Pfizer nabs FDA nod for another targeted cancer drug
- BREAKING: FDA (finally) stamps an approval on Amylin's Bydureon
- Biogen's lead dealmaker makes case against corporate VC
- Merger mania? Or did back-to-back buyouts stoke a media frenzy?
- Big Pharma chiefs balk at bidding against Roche for Illumina
